Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | SAR444200 |
Trade Name | |
Synonyms | SAR-444200|SAR 444200 |
Drug Descriptions |
SAR444200 is a nanobody T-cell engager that binds to both TCR alpha/beta and GPC3, directing cytotoxic T cells to GPC3-expressing tumors, potentially leading to T cell-dependent cellular toxicity (Ann Oncol (2023) 34 (suppl_2): S634). |
DrugClasses | GPC3 Antibody 5 |
CAS Registry Number | NA |
NCIT ID | C199578 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + SAR444200 | Atezolizumab SAR444200 | 0 | 1 |
Cemiplimab + SAR444200 | Cemiplimab SAR444200 | 0 | 0 |
SAR444200 | SAR444200 | 0 | 1 |